Payment overview · 2025
General Payments
$151.43
8 reported records · 5 companies
Healthcare provider profile · identity verified
Ashwin N Raval, MD
Allopathic & Osteopathic Physicians|Family Medicine · RIVERVIEW, MI · NPI 1558369132
Verified facts
What the public records show
CMS Open Payments records show Ashwin N Raval, MD received $151.43 in general payments during 2025 across 8 reported records.
Exact Sciences Corporation accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $82.46 | 54.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.00 | 12.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.70 | 11.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.53 | 11.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.74 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.43 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $82.46 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 700 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 113 |
| Losartan Potassium | Losartan Potassium | 424 | 87 |
| Metformin Hcl | Metformin Hcl | 381 | 86 |
| Alprazolam | Alprazolam | 358 | 54 |
| Omeprazole | Omeprazole | 314 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 249 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 237 | 57 |
| Meloxicam | Meloxicam | 227 | 64 |
| Lisinopril | Lisinopril | 211 | 50 |
| Gabapentin | Gabapentin | 203 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 52 |
| Tramadol Hcl | Tramadol Hcl | 175 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 37 |
| Metformin Hcl Er | Metformin Hcl | 144 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 143 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 40 |
| Lorazepam | Lorazepam | 135 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 34 |
| Simvastatin | Simvastatin | 128 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 27 |
| Trulicity | Dulaglutide | 120 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 29 |
| Sertraline Hcl | Sertraline Hcl | 106 | 21 |
| Trazodone Hcl | Trazodone Hcl | 106 | 25 |
| Glimepiride | Glimepiride | 104 | 29 |
| Jardiance | Empagliflozin | 98 | 25 |
| Furosemide | Furosemide | 92 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 21 |
| Allopurinol | Allopurinol | 84 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 63 |
| Carvedilol | Carvedilol | 78 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 14 |
| Ezetimibe | Ezetimibe | 63 | 18 |
| Amoxicillin | Amoxicillin | 62 | 50 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Atenolol | Atenolol | 48 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 13 |
| Cephalexin | Cephalexin | 38 | 33 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 17 |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 25 |
| Naproxen | Naproxen | 27 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 11 |
| Risedronate Sodium | Risedronate Sodium | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | 11 |
| Pregabalin | Pregabalin | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.43 · 8 records | Exact Sciences Corporation | Cologuard Collection Kit, EVENITY, FARXIGA, Ohtuvayre, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error